Pharming Group (NASDAQ:PHAR) Trading Down 4%

Pharming Group (NASDAQ:PHAR) shares dropped 4% on Friday . The stock traded as low as $7.47 and last traded at $7.47. Approximately 777 shares traded hands during mid-day trading, a decline of 82% from the average daily volume of 4,375 shares. The stock had previously closed at $7.78.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $37.00 target price on shares of Pharming Group in a research note on Thursday, August 1st.

Pharming Group Price Performance

The company has a quick ratio of 2.65, a current ratio of 3.39 and a debt-to-equity ratio of 0.40. The company’s 50 day simple moving average is $8.09 and its two-hundred day simple moving average is $9.38.

Pharming Group (NASDAQ:PHAR) last announced its earnings results on Thursday, August 1st. The company reported ($0.01) earnings per share for the quarter. The firm had revenue of $74.09 million during the quarter, compared to analyst estimates of $71.95 million. Pharming Group had a negative net margin of 4.65% and a negative return on equity of 5.69%. During the same quarter last year, the business earned $0.02 earnings per share. On average, equities analysts predict that Pharming Group will post -0.03 earnings per share for the current fiscal year.

Institutional Trading of Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its position in Pharming Group (NASDAQ:PHAR) by 32.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 23,435 shares of the company’s stock after purchasing an additional 5,725 shares during the quarter. Silverberg Bernstein Capital Management LLC’s holdings in Pharming Group were worth $196,000 as of its most recent SEC filing. 0.03% of the stock is owned by hedge funds and other institutional investors.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.